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Abstract:
Objectives: Trimethoprim-sulfamethoxazole (TMP/SMX) combination is 
used for the prophylaxis of Pneumocystis pneumonia (PCP). Although 
TMP/SMX is frequently used in dermatology for cases treated with 
corticosteroids and/or immunosuppressants, it is often difficult to 
continue the administration of TMP/SMX due to adverse events. There 
are only a few reported studies on the prophylaxis of PCP in 
dermatology. This is the first review focused on adverse events of 
TMP/SMX among patients with dermatological diseases compared to 
previous reports. 
Methods: In this study, we retrospectively investigated 132 cases 
treated with TMP/SMX and examined the adverse events. 
Results: Adverse events occurred in 32 cases (24.2%), and the incidence 
in this study was higher than in previous reports. Thrombocytopenia 
occurred in 17 cases (12.5%), which was the most frequent adverse 
event. The possible causes of adverse events were the standard dose of 
TMP/SMX might be excess for most Japanese, in addition to the long 
administration period, and the concomitant use of corticosteroids and/or 
immunosuppressants in almost all cases. 
Conclusion: We must consider the risks of PCP and adverse events of 
TMP/SMX in each case. It is desirable to examine possible administration 
methods that can be continued by adjusting the dose and interval of 
TMP/SMX.
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2 Objectives: Trimethoprim-sulfamethoxazole (TMP/SMX) combination is 
3 used for the prophylaxis of Pneumocystis pneumonia (PCP). Although 
4 TMP/SMX is frequently used in dermatology for cases treated with 
5 corticosteroids and/or immunosuppressants, it is often difficult to continue 
6 the administration of TMP/SMX due to adverse events. There are only a 
7 few reported studies on the prophylaxis of PCP in dermatology. This is the 
8 first review focused on adverse events of TMP/SMX among patients with 
9 dermatological diseases compared to previous reports.
10 Methods: In this study, we retrospectively investigated 132 cases treated 
11 with TMP/SMX and examined the adverse events. 
12 Results: Adverse events occurred in 32 cases (24.2%), and the incidence in 
13 this study was higher than in previous reports. Thrombocytopenia occurred 
14 in 17 cases (12.5%), which was the most frequent adverse event. The 
15 possible causes of adverse events were the standard dose of TMP/SMX 
16 might be excess for most Japanese, in addition to the long administration 
17 period, and the concomitant use of corticosteroids and/or 
18 immunosuppressants in almost all cases.
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1 Conclusion: We must consider the risks of PCP and adverse events of 
2 TMP/SMX in each case. It is desirable to examine possible administration 
3 methods that can be continued by adjusting the dose and interval of 
4 TMP/SMX.
5




10 Pneumocystis pneumonia (PCP) is a serious disease caused by 
11 Pneumocystis jirovecii, and the survival rate is 52.9% for dermatology 
12 patients.1 It develops in the background of underlying diseases, such as 
13 AIDS, malignant tumors, and collagen diseases treated with high-dose 
14 corticosteroids and/or immunosuppressants.       
15 Trimethoprim-sulfamethoxazole (TMP/SMX) combination has been 
16 reported to have a preventive effect against PCP.2 Dermatologists 
17 frequently administer TMP/SMX to patients with pemphigus, pemphigoid, 
18 dermatomyositis, and systemic lupus erythematosus. Because we treat 
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1 these patients with corticosteroids and/or immunosuppressants for a long 
2 period of time, adverse events often occur, so we often reduce the dose of 
3 TMP/SMX due to adverse events.3 We have managed to use TMP/SMX 
4 without causing adverse events.4 A non-blind randomized controlled trial is 
5 now in progress.5 However, there are only a few reported studies on the 
6 prophylaxis of PCP in dermatology.6 In this study, we investigated the 
7 frequency of adverse events in patients with dermatological diseases who 
8 received TMP/SMX for the prophylaxis of PCP.
9
10 Methods
11 Patients: We enrolled patients with dermatological diseases who were 
12 hospitalized at the Department of Dermatology of Shiga University of 
13 Medical Science and who received TMP/SMX for prophylaxis of PCP 
14 from July 2010 to October 2017. We administered TMP/SMX to patients 
15 who were treated with high-dose corticosteroids (>20 mg/day for 1 
16 month, until reduced approximately <10 mg/day). 
17 Study design: A retrospective review of 132 patients who were 
18 administered TMP/SMX was conducted. Each tablet of TMP/SMX 
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1 included 80 mg TMP and 400 mg SMX. We administered TMP/SMX at 
2 the dosage of 1 tablet daily, 0.5 tablet daily, 1 tablet every other day, 2 
3 tablets twice weekly, or 2 tablets daily depending on the case without 
4 specific rules. Data included age, sex, primary diseases, dosage of 
5 TMP/SMX, presence or absence of adverse events, and their contents. 
6 Follow-up period was from July 2010 to October 2017. We regarded 
7 adverse events in cases for whom other causes for the events were 
8 excluded, TMP/SMX was needed to be reduced or discontinued, and then 
9 confirmed an improvement of adverse events. Instead of rechallenge, we 
10 administered atovaquone or pentamidine isethionate by inhalation. This 
11 study was approved by the Research Ethics Committee of Shiga University 
12 of Medical Science (reference number R2017-221).
13 Statistical analysis: We collected the case data and compared the incidence 
14 of adverse events for each primary disease, dosage of TMP/SMX, presence 
15 or absence of concomitant drugs, and patients’ ages. Statistical analysis 
16 was performed using χ2 test or Student’s t-test.
17
18 Results
Page 6 of 18
The Journal of Dermatology































































1 Patient characteristics: A total of 132 patients were enrolled (60 males and 
2 72 females aged 17 to 49 years; Table 1). The primary diseases were 
3 bullous pemphigoid (28 patients), dermatomyositis (22 patients), 
4 pemphigus vulgaris (9 patients), pyoderma gangrenosum (7 patients), adult 
5 Still’s disease (6 patients), malignant lymphoma (5 patients), systemic 
6 lupus erythematosus (5 patients), pemphigus foliaceus (5 patients), and 
7 others (45 patients). Adverse events occurred below 13 years old (0 case), 
8 at 13 to 65 years old (20 of 72 cases; 27.8%), and above 65 years old (12 of 
9 60 cases; 20.0%). There was no statistical significance in the incidence of 
10 adverse events between their age, sex, and primary diseases. 
11 Incidence of adverse events: Although no patients developed PCP, adverse 
12 events occurred in 32 cases (24.2%). Adverse events included 
13 erythrocytopenia (2.2%), leukocytopenia (2.2%), thrombocytopenia 
14 (12.5%), elevated liver enzyme (5.9%), renal dysfunction (1.5%), and drug 
15 eruption (4.5%). Out of 6 drug eruptions, 5 cases were maculopapular 
16 eruption (day10, 11, 12, 21, 30), and 1 case was toxic epidermal necrolysis 
17 (day 11). Adverse events occurred at the dosage of 1 tablet daily (29 of 115 
18 cases), 0.5 tablet daily (1 of 7 cases), 2 tablets daily (1 of 2 cases), 2 tablets 
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1 twice weekly (0 of 6 cases), and 1 tablet every other day (1 of 2 cases). We 
2 summarized the incidence of adverse events in this study and from previous 
3 reports (Table 2).7-10 The incidence of hematologic problem and elevated 
4 liver enzyme in this study (daily administration; n = 124) was significantly 
5 higher than that of El-Sadr, et al. (daily administration; n = 1312). There 
6 are no relationship and significant difference between the accumulated 
7 doses of TMX/SMX and onset of adverse events.
8 Time of onset of adverse events: The time of onset of adverse events was 
9 within 1 week (18.8%), from 1 week to 1 month (26.3%), and more than 1 
10 month (25.0%). We created a box-and-whisker plot that shows the day of 
11 onset of each adverse event (Figure 1). The onset of adverse events was on 
12 days 2 to 66; renal dysfunction most often occurred at about 1 week, 
13 elevated liver enzyme and drug eruption at about 2 weeks, and cytopenia at 
14 about 2 to 3 weeks. There were no significant differences in the day of 
15 onset of each adverse event.
16
17 Discussion
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1 In our study, there were significant differences in the incidence of 
2 hematologic problem and elevated liver enzyme.7-10 Of course, we could 
3 not simply compare these results due to the difference of primary diseases, 
4 observation period, and definition of adverse events. We discuss three 
5 perspectives for these results. (1) Prophylaxis of TMX/SMX needs longer-
6 term than administration as a treatment of an infection, which may increase 
7 the chances of adverse events. Although cytopenia was relatively rare in a 
8 treatment of infection, it was frequently seen in our study: erythrocytopenia 
9 (2.6%), leukocytopenia (2.2%), and thrombocytopenia (12.5%). It was 
10 considered that TMP/SMX caused cytopenia by impairing folic acid 
11 metabolism and that long-term administration might cause metabolic 
12 abnormalities and folate deficiency depending on the period, resulting in 
13 increased incidence of cytopenia.11 However, there were no significant 
14 difference between the accumulated doses of TMX/SMX and onset of 
15 adverse events. It is not clear whether an administration period is related to 
16 the incidence of the adverse events. 
17  (2) We treated our patients with combined medication of corticosteroids 
18 and/or immunosuppressants for primary diseases in almost all cases. 
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1 Immunocompromised patients sometimes needed other various drugs, for 
2 example, ganciclovir for cytomegalovirus infection, which might have 
3 interacted with TMP/SMX. (3) In Table 2, the results of El-Sadr WM et al. 
4 showed that the dosage of TMP/SMX apparently involved the incidence of 
5 adverse events. One study proved that there was a significant dose-
6 dependent increasing trend in adverse events of TMP/SMX.12 For Japanese, 
7 it might be better to reduce the dose or frequency of TMP/SMX, although 
8 we could not prove that the incidence of adverse events was related the race 
9 or BMI of patients. There are no reports that discussed whether or not we 
10 can reduce the dosage of TMP/SMX in safety.
11 It was reported that the incidence of adverse events with thrice-weekly 
12 administration of TMP/SMX was significantly lower than that with daily 
13 administration, and there was no significant difference in the PCP 
14 incidence rate between daily and thrice-weekly administration.9 The results 
15 of our study were similar to that of previous reports, although the number 
16 of cases was limited.
17 Although we should be cautious of adverse events, some reports showed 
18 that the odds ratio of PCP development due to discontinuation of 
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1 TMP/SMX is 4.77 times in HIV-infected patients.9 Guidelines in the 
2 United States suggested that we better eventually restart TMP/SMX for 
3 cases in which it was discontinued due to a mild adverse event. 
4 Approximately 70% of patients were able to continue TMP/SMX by 
5 reducing the dose/interval or desensitization therapy.13 
6 Although the mechanism of adverse effects of TMP/SMX and the risk 
7 factors have been almost clear,11 we need to be cautious of the occurrence 
8 of adverse events of TMP/SMX for each case. One study reported that 
9 routine prophylaxis is unnecessary for patients with autoimmune blistering 
10 diseases, who do not usually need strong immunosuppression.14 We should 
11 consider the risks of PCP and adverse events of TMP/SMX in each case, as 
12 necessary, and examine possible administration methods that can be 
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6 Table 1. Patient characteristics 
7 Table 2. The incidence of adverse events comparison with previous reports
8 * Daily administered cases of this study versus daily administered cases of 
9 El-Sadr WM, et al.
10 HIV: human immunodeficiency virus; LT: liver transplantation; ND: Not 
11 described; RD: Rheumatic diseases
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Figure 1. Box-and-whisker plot shows the day of onset of each adverse event 
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(n= 32) P value
Age (average± standard deviation) 60.6± 17.8 59.0± 18.0 0.54
Sex (man/woman) 60/72 10/22 1
Primary disease
Bullous pemphigoid (%) 28 7 (25%) 0.97
Dermatomyositis (%) 22 6 (27.7%) 0.9
Pemphigus vulgaris (%) 9 3 (33.3%) 0.83
Pyoderma gangrenosum (%) 7 1 (14.3%) 0.82
Adult still's disease (%) 6 2 (33.3%) 0.86
Malignant lymphoma (%) 5 1 (20%) 0.94
Systemic lupus erythematosus (%) 5 2 (40%) 0.78
Pemphigus foliaceus (%) 5 1 (20%) 0.94
Others (%) 45 9 (20%) 0.78
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Table 2 The incidence of adverse events comparison with previous reports
This study #7 #8 #9 #10














































































































































































































*Daily administered cases of this study versus daily administered cases of El-Sadr WM, et al. 
HIV: human immunodeficiency virus; LT: liver transplantation; 
ND: Not described; RD: Rheumatic diseases
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